FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
ı	haura nar raananaa.	٥٦								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HENNEMAN JOHN B III						2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]							(Che	eck all applic Directo	tionship of Reporting all applicable) Director Officer (give title below)		on(s) to Issu 10% Ow Other (s below)	ner
(Last) (First) (Middle) 311 C ENTERPRISE DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2003								Exe	VP, CA	0 & 9	Secretary		
(Street) PLAINSBORO NJ 08536			_   4. _	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)		,	(Zip)										<u> </u>					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)						tion 2A. Deemed Execution Date,		3. 4. Securities Transaction Disposed O Code (Instr.		es Acquired (A) or of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)			(Instr. 4)
Common Stock 12/31/20							003 <sup>(1)</sup> 12/31/2003		I		1,416	A	\$15.002	25	104	.04		
			Table II								osed of, convertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transa Code ( 8)				6. Date Exercis Expiration Date (Month/Day/Yea		e	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab	ole	Expiration Date	Title	Amount or Number of Shares					
Incentive Stock Option (right to buy)	\$28.78	01/02/2004	01/02/2	01/02/2004			846		01/02/200	)5 <sup>(2)</sup>	01/02/2010	Common Stock	846	\$0.00	846		D	
Non- Qualified Stock Option (right to	\$28.78	01/02/2004	01/02/2004		A		24,154		01/02/200	)5 <sup>(2)</sup>	01/02/2010	Common Stock	24,154	\$0.00	24,154	4	D	

## Explanation of Responses:

- 1. Shares acquired pursuant to Integra LifeSciences' 1998 Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3.
- 2. 25% of the options vest one year after the grant date, with the remaining 75% vesting monthly thereafter 36 months.

<u>/s/ John B. Henneman, III</u> <u>01/05/2004</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.